Medtech small cap BioSig confirms Nasdaq compliance, shares jump

Shares of small-cap medtech company BioSig Technologies, which makes devices to detect heart rhythm disorders, surged 11% yesterday, March 26, after the company announced its shares would keep trading on the Nasdaq. Last year, BioSig faced delisting because of noncompliance with listing requirements.  

BioSig jumped 11.4% to close at $0.59 per share yesterday, with the intraday gain as high as 16%. Still, the closing price marked the highest in a week.  

Yesterday, the company announced it had received an official notice from Nasdaq confirming that its shares would continue trading on the exchange after BioSig had met the minimum stockholders’ equity requirement of $2.5 million.  

The risk of delisting emerged in 2024, when on June 10, BioSig was notified of its noncompliance with the requirement.  

On June 12, trading in BioSig common shares was suspended on the Nasdaq. The company appealed the decision and, while it awaited a resolution with Nasdaq, moved to the OTCQB market, managed by OTC Markets Group. In October, BioSig secured a five-month extension to regain compliance and resumed trading on the Nasdaq. The news sent the stock soaring 34%.  

BioSig is developing a proprietary biomedical signal processing platform to diagnose abnormal heart rates and rhythms. By combining hardware and software, its technology is said to enhance the clarity of cardiac signals, improving the accuracy of arrhythmia detection and treatment.  

The company’s flagship product is PURE EP, an FDA-approved, noninvasive device that provides advanced visualization of critical physiologic information for intracardiac signals.  

BioSig has been highly volatile. Since the start of 2025, it is down 60%, yet over the last six months, it is up nearly 80%.  

According to MarketWatch, BioSig has only one analyst rating, which is a “buy.” The target price is $2.75 per share, implying upside of 466% versus the last closing price.